A complete list of the side effects of Eltrombopag/Eltrombopag, a must-read before taking the medication!

Eltrombopag is a drug used to treat immune thrombocytopenia (ITP) and other thrombocytopenias caused by disorders of myelopoiesis. As a thrombopoietic drug, eltrombopag stimulates the production of platelets in the bone marrow by activating the thrombopoietic factor receptor (TPO receptor). While eltrombopag provides an effective treatment option for many patients, it also carries a certain risk of side effects. Understanding these side effects is important for pre-medication decision-making and subsequent monitoring.

The most common side effect of eltrombopag is abnormal liver function. In clinical trials, some patients developed liver function impairment after taking eltrombopag, manifested by elevated transaminases. Especially with long-term use or high doses, the risk of liver damage is higher. Therefore, doctors usually recommend that patients regularly check liver function during treatment so that potential liver damage problems can be detected and dealt with in a timely manner. If liver function abnormalities occur, drug dosage may need to be adjusted or treatment discontinued.

Gastrointestinal effects of eltrombopag are also common side effects. Patients may experience symptoms such as nausea, vomiting, loss of appetite, and abdominal pain, which are usually more common in the first few weeks of treatment. These mild gastrointestinal discomforts can be relieved by adjusting your diet or taking medication after meals. However, if symptoms are severe or persist for a long time, you should seek prompt medical evaluation.

In addition, eltrombopag may cause headaches, joint pain and other symptoms. Although these side effects are usually mild, for some patients, they may affect daily life. In addition, some patients may experience skin reactions such as rash while taking eltrombopag. Although these reactions are rare, if significant discomfort occurs, patients should communicate with their doctor promptly to evaluate whether the treatment plan needs to be adjusted.

Reference materials:https://go.drugbank.com/drugs/DB06210